Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
By
Dan Schiff / Email the Author / “The Tan Sheet” Jan. 16, 2012, Vol. 20, No. 03
Business & Finance / Word Count: 1080 / Article # 05120116002
Executive Summary
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.